Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury (NESAKI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01122225|
Recruitment Status : Unknown
Verified April 2010 by Université Victor Segalen Bordeaux 2.
Recruitment status was: Active, not recruiting
First Posted : May 13, 2010
Last Update Posted : May 31, 2010
Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels.
The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.
|Condition or disease|
|Acute Kidney Failure|
Primary Outcome Measures:
To correlate elevated serum NGAL with the diagnosis of intrinsic acute kidney injury in septic shock
Secondary Outcome Measures :
To compare serum NGAL with serum creatinine, serum urea and urine output in septic AKI Death within the intensive care unit Death from all causes at 28 days after inclusion
|Study Type :||Observational|
|Actual Enrollment :||50 participants|
|Official Title:||Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||May 2010|
|Estimated Study Completion Date :||June 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122225
|Reanimation medicale, Hopital Saint-Andre, Bordeaux University Hospital|
|Bordeaux, Aquitaine, France, 33000|
|Principal Investigator:||Fabrice Camou, MD||University Hospital, Bordeaux|